{"id":"mepivacaine-hydrochloride","_fda":{"id":"d65ce2b4-0c6a-4edd-bb95-c7f463db8dd4","set_id":"042010fb-7161-4336-b91f-5a25839ee644","openfda":{"unii":["4VFX2L7EM5"],"route":["SUBMUCOSAL"],"rxcui":["1305263"],"spl_id":["d65ce2b4-0c6a-4edd-bb95-c7f463db8dd4"],"brand_name":["Mepivacaine"],"spl_set_id":["042010fb-7161-4336-b91f-5a25839ee644"],"package_ndc":["43128-005-35"],"product_ndc":["43128-005"],"generic_name":["MEPIVACAINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["MEPIVACAINE HYDROCHLORIDE"],"manufacturer_name":["NDC, Inc."],"application_number":["ANDA088387"],"is_original_packager":[true]},"version":"6","warnings":["WARNINGS RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE. (See ADVERSE REACTIONS). Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics, even in the absence of a history of hypersensitivity. Fatalities may occur with use of local anesthetics in the head and neck region as the result of retrograde arterial flow to vital CNS areas even when maximum recommended doses are observed. The practitioner should be alert to early evidence of alteration in sensorium or vital signs. The solution which contains a vasoconstrictor (Mepivacaine HCl 2% (20 mg/mL)) should be used with extreme caution for patients whose medical history and physical evaluation suggest the existence of hypertension, arteriosclerotic heart disease, cerebral vascular insufficiency, heart block, thyrotoxicosis and diabetes, etc. The solution which contains a vasoconstrictor (Mepivacaine HCl 2% (20 mg/mL)) also contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and lifethreatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. Mepivacaine HCl 3% (30 mg/mL) is SULFITE FREE. Mepivacaine, along with other local anesthetics, is capable of producing methemoglobinemia. The clinical signs of methemoglobinemia are cyanosis of the nail beds and lips, fatigue and weakness. If methemoglobinemia does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended. The American Heart Association has made the following recommendations regarding the use of local anesthetics with vasoconstrictors in patients with ischemic heart disease: “Vasoconstrictor agents should be used in local anesthesia solutions during dental practice only when it is clear that the procedure will be shortened or the analgesia rendered more profound. When a vasoconstrictor is indicated, extreme care should be taken to avoid intravascular injection. The minimum possible amount of vasoconstrictor should be used.” (Kaplan, EL, editor: Cardiovascular disease in dental practice, Dallas 1986, American Heart Association.) Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use; MEPIVACAINE, along with other local anesthetics, is capable of producing this condition. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by cyanosis of the skin, nail beds and lips, and/or abnormal coloration of the blood, fatigue and weakness. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue MEPIVACAINE and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. If methemoglobinemia does not respond to administration of oxygen, a more severe clinical presentation may require treatment with methylene blue exchange transfusion, or hyperbaric oxygen."],"pregnancy":["Pregnancy Teratogenic Effects: Pregnancy Category C: Animal reproduction studies have not been conducted with this solution. It is also not known whether this solution can cause fetal harm when administered to a pregnant woman or can effect reproductive capacity. This solution should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE Treatment of a patient with toxic manifestations consists of assuring and maintaining a patent airway and supporting ventilation (respiration) as required. This usually will be sufficient in the management of most reactions. Should a convulsion persist despite ventilatory therapy, small increments of anticonvulsive agents may be given intravenously, such as benzodiazephine (e.g., diazepam) or ultrashort-acting barbiturates (e.g., thiopental or thiamylal) or short-acting barbiturates (e.g., pentobarbital or secobarbital). Cardiovascular depression may require circulatory assistance with intravenous fluids and/or vasopressor (e.g., Ephedrine) as dictated by the clinical situation. Allergic reactions should be managed by conventional means. IV and SC LD 50 's in mice for Mepivacaine Hydrochloride 3% are 33 and 258 mg/kg, respectively. The acute IV and SC LD 50 's in mice for Mepivacaine Hydrochloride 2% with Levonordefrin 1:20,000 are 30 and 184 mg/kg, respectively."],"description":["DESCRIPTION Mepivacaine Hydrochloride, a tertiary amine used as a local anesthetic, is 1-methyl-2', 6' - pipecoloxylidide monohydrochloride with the following structural formula: It is a white, crystalline, odorless powder soluble in water, but very resistant to both acid and alkaline hydrolysis. Levonordefrin, a sympathomimetic amine used as a vasoconstrictor in local anesthetic solution, is (-)- -(1-Aminoethyl)-3, 4-dihydroxybenzyl alcohol with the following structural formula: It is a white or buff-colored crystalline solid, freely soluble in aqueous solutions of mineral acids, but practically insoluble in water; DENTAL CARTRIDGES MAY NOT BE AUTOCLAVED. Mepivacaine hydrochloride injection 3% (30 mg/mL) and Mepivacaine hydrochloride 2% (20 mg/mL) with levonordefrin 1:20,000 injection are sterile solutions for injection. Chemical Structure Chemical Structure Chemical Structure"],"precautions":["PRECAUTIONS The safety and effectiveness of Mepivacaine depend upon proper dosage, correct technique, adequate precautions, and readiness for emergencies. The lowest dose that results in effective anesthesia should be used to avoid high plasma levels and possible adverse effects. Injection of repeated doses of Mepivacaine may cause significant increases in blood levels with each repeated dose due to slow accumulation of the drug or its metabolites, or due to slower metabolic degradation than normal. Tolerance varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their weight and physical status. Mepivacaine should be used with caution in patients with a history of severe disturbances of cardiac rhythm or heart block. INJECTIONS SHOULD ALWAYS BE MADE SLOWLY WITH ASPIRATION TO AVOID INTRAVASCULAR INJECTION AND THEREFORE SYSTEMIC REACTION TO BOTH LOCAL ANESTHETIC AND VASOCONSTRICTOR. If sedatives are employed to reduce patient apprehension, use reduced doses, since local anesthetic agents, like sedatives, are central nervous system depressants which in combination may have an additive effect. Young children should be given minimal doses of each agent. Changes in sensorium such as excitation, disorientation or drowsiness may be early indications of a high blood level of the drug and may occur following inadvertent intravascular administration or rapid absorption of Mepivacaine. Local anesthetic procedures should be used with caution when there is inflammation and/or sepsis in the region of the proposed injection. Information for Patients/Patient Counseling Information: The patient should be cautioned against loss of sensation and possibility of biting trauma should the patient attempt to eat or chew gum prior to return of sensation. Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue. Clinically Significant Drug Interactions The administration of local anesthetic solutions containing vasopressors, such as Levonordefrin, Epinephrine or Norepinephrine, to patients receiving tricyclic antidepressants or monoamine oxidase inhibitors may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of Epinephrine. Solutions containing a vasoconstrictor should be used cautiously in the presence of disease which may adversely affect the patient's cardiovascular system. Serious cardiac arrhythmias may occur if preparations containing a vasoconstrictor are employed in patients during or following the administration of potent inhalation anesthetics. Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: EXAMPLES OF DRUGS ASSOCIATED WITH METHEMOGLOBINEMIA: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprus-side, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hy-droxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine MEPIVACAINE SHOULD BE USED WITH CAUTION IN PATIENTS WITH KNOWN DRUG ALLERGIES AND SENSITIVITIES. A thorough history of the patient's prior experience with Mepivacaine or other local anesthetics as well as concomitant or recent drug use should be taken (see CONTRAINDICATIONS ). Patients allergic to methylparaben or para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross-sensitivity to agents of the amide type such as Mepivacaine. Since Mepivacaine is metabolized in the liver and excreted by the kidneys, it should be used cautiously in patients with liver and renal disease. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of Mepivacaine HCl in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted. Pregnancy Teratogenic Effects: Pregnancy Category C: Animal reproduction studies have not been conducted with this solution. It is also not known whether this solution can cause fetal harm when administered to a pregnant woman or can effect reproductive capacity. This solution should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this solution is administered to a nursing woman. Pediatric Use Great care must be exercised in adhering to safe concentrations and dosages for pedodontic administration (see DOSAGE AND ADMINISTRATION )."],"how_supplied":["HOW SUPPLIED Mepivacaine HCl 3% (30 mg/mL); (Mepivacaine Hydrocholoride Injection USP) is available in cardboard boxes containing 5 blisters of 10 x 1.7 mL single-dose dental cartridges, 50 per carton. Mepivacaine HCl 2% (20 mg/mL) (Mepivacaine Hydrochloride and Levonordefrin Injection; USP) is available in cardboard boxes containing 5 blisters of 10 x 1.7 mL single-dose dental cartridges, 50 per carton. Both solutions should be stored at controlled room temperature, below 25° C (77° F). Protect from light. Do not permit to freeze. BOXES: For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap. The Mepivacaine 2% (20 mg/mL) solution should not be used if its color is pinkish or darker than slightly yellow or it contains a precipitate. Cartridge warmers should not be used with Mepivacaine HCl Injection USP products."],"pediatric_use":["Pediatric Use Great care must be exercised in adhering to safe concentrations and dosages for pedodontic administration (see DOSAGE AND ADMINISTRATION )."],"effective_time":"20240221","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this solution is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS Reactions to Mepivacaine are characteristic of those associated with other amide-type local anesthetics. Systemic adverse reactions involving the central nervous system and the cardiovascular system usually result from high plasma levels (which may be due to excessive dosage, rapid absorption, inadvertent intravascular injection, or slow metabolic degradation), injection technique, or volume of injection. A small number of reactions may result from hypersensitivity, idiosyncrasy or diminished tolerance to normal dosage on the part of the patient. Persistent paresthesias of the lips, tongue, and oral tissues have been reported with the use of mepivacaine, with slow, incomplete, or no recovery. These post-marketing events have been reported chiefly following nerve blocks in the mandible and have involved the trigeminal nerve and its branches. Reactions involving the central nervous system are characterized by excitation and/or depression. Nervousness, dizziness, blurred vision, or tremors may occur followed by drowsiness, convulsions, unconsciousness, and possible respiratory arrest. Since excitement may be transient or absent, the first manifestations may be drowsiness merging into unconsciousness and respiratory arrest. Cardiovascular reactions are depressant. They may be the result of direct drug effect or more commonly in dental practice, the result of vasovagal reaction, particularly if the patient is in the sitting position. Failure to recognize premonitory signs such as sweating, feeling of faintness, changes in pulse or sensorium may result in progressive cerebral hypoxia and seizure or serious cardiovascular catastrophe. Management consists of placing the patient in the recumbent position and administration of oxygen. Vasoactive drugs such as Ephedrine or Methoxamine may be administered intravenously. Allergic reactions are rare and may occur as a result of sensitivity to the local anesthetic and are characterized by cutaneous lesions of delayed onset or urticaria, edema and other manifestations of allergy. The detection of sensitivity by skin testing is of limited value. As with other local anesthetics, anaphylactoid reactions to Mepivacaine have occurred rarely. The reaction may be abrupt and severe and is not usually dose related. Localized puffiness and swelling may occur."],"contraindications":["CONTRAINDICATIONS Mepivacaine is contraindicated in patients with a known hypersensitivity to amide-type local anesthetics."],"drug_interactions":["Clinically Significant Drug Interactions The administration of local anesthetic solutions containing vasopressors, such as Levonordefrin, Epinephrine or Norepinephrine, to patients receiving tricyclic antidepressants or monoamine oxidase inhibitors may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of Epinephrine. Solutions containing a vasoconstrictor should be used cautiously in the presence of disease which may adversely affect the patient's cardiovascular system. Serious cardiac arrhythmias may occur if preparations containing a vasoconstrictor are employed in patients during or following the administration of potent inhalation anesthetics. Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: EXAMPLES OF DRUGS ASSOCIATED WITH METHEMOGLOBINEMIA: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprus-side, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hy-droxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine MEPIVACAINE SHOULD BE USED WITH CAUTION IN PATIENTS WITH KNOWN DRUG ALLERGIES AND SENSITIVITIES. A thorough history of the patient's prior experience with Mepivacaine or other local anesthetics as well as concomitant or recent drug use should be taken (see CONTRAINDICATIONS ). Patients allergic to methylparaben or para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross-sensitivity to agents of the amide type such as Mepivacaine. Since Mepivacaine is metabolized in the liver and excreted by the kidneys, it should be used cautiously in patients with liver and renal disease."],"precautions_table":["
EXAMPLES OF DRUGS ASSOCIATED WITH METHEMOGLOBINEMIA:
ClassExamples
Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprus-side, nitrous oxide
Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine
Antineoplastic Agents cyclophosphamide, flutamide, hy-droxyurea, ifosfamide, rasburicase
Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides
Antimalarials chloroquine, primaquine
Anticonvulsants Phenobarbital, phenytoin, sodium valproate
Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine
"],"storage_and_handling":["Both solutions should be stored at controlled room temperature, below 25° C (77° F). Protect from light. Do not permit to freeze. BOXES: For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap. The Mepivacaine 2% (20 mg/mL) solution should not be used if its color is pinkish or darker than slightly yellow or it contains a precipitate. Cartridge warmers should not be used with Mepivacaine HCl Injection USP products."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Mepivacaine stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia. Mepivacaine is rapidly metabolized, with only a small percentage of the anesthetic (5 to 10 percent) being excreted unchanged in the urine. Mepivacaine because of its amide structure, is not detoxified by the circulating plasma esterases. The liver is the principal site of metabolism, with over 50 percent of the administered dose being excreted into the bile as metabolites. Most of the metabolized Mepivacaine is probably resorbed in the intestine and then excreted into the urine since only a small percentage is found in the feces. The principal route of excretion is via the kidney. Most of the anesthetic and its metabolites are eliminated within 30 hours. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of Mepivacaine have been identified from adult humans: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2’, 6’ - pipecoloxylidide). The onset of action is rapid (30 to 120 seconds in the upper jaw; 1 to 4 minutes in the lower jaw) and Mepivacaine HCl 3% (30 mg/mL) will ordinarily provide operating anesthesia of 20 minutes in the upper jaw and 40 minutes in the lower jaw. Mepivacaine HCl 2% (20 mg/mL) with Levonordefrin 1:20,000 provides anesthesia of longer duration for more prolonged procedures, 1 hour to 2.5 hours in the upper jaw and 2.5 hours to 5.5 hours in the lower jaw. Mepivacaine does not ordinarily produce irritation or tissue damage. Levonordefrin is a sympathomimetic amine used as a vasoconstrictor in local anesthetic solutions. It has pharmacologic activity similar to that of Epinephrine but it is more stable than Epinephrine. In equal concentrations, Levonordefrin is less potent than Epinephrine in raising blood pressure, and as a vasoconstrictor."],"indications_and_usage":["INDICATIONS AND USAGE Mepivacaine is indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and pediatric patients."],"drug_interactions_table":["
EXAMPLES OF DRUGS ASSOCIATED WITH METHEMOGLOBINEMIA:
ClassExamples
Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprus-side, nitrous oxide
Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine
Antineoplastic Agents cyclophosphamide, flutamide, hy-droxyurea, ifosfamide, rasburicase
Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides
Antimalarials chloroquine, primaquine
Anticonvulsants Phenobarbital, phenytoin, sodium valproate
Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine
"],"information_for_patients":["Information for Patients/Patient Counseling Information: The patient should be cautioned against loss of sensation and possibility of biting trauma should the patient attempt to eat or chew gum prior to return of sensation. Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue."],"spl_unclassified_section":["Rx Only THESE SOLUTIONS ARE INTENDED FOR DENTAL USE ONLY.","COMPOSITION CARTRIDGE Each mL contains: 2% 3% Mepivacaine Hydrochloride 20 mg 30 mg Levonordefrin 0.05 mg - Sodium Chloride 4 mg 6 mg Potassium metabisulfite 1.2 mg - Edetate disodium 0.25 mg - Sodium Hydroxide q.s. ad pH; Hydrochloric Acid 0.5 mg - Water For Injection, qs. ad. 1 mL 1 mL The pH of the 2% cartridge solution is adjusted between 3.3 and 5.5 with NaOH. The pH of the 3% cartridge solution is adjusted between 4.5 and 6.8 with NaOH.","DISINFECTION OF CARTRIDGES As in the case of any cartridge, the diaphragm should be disinfected before needle puncture. The diaphragm should be thoroughly swabbed with either pure 91% isopropyl alcohol or 70% ethyl alcohol, USP, just prior to use. Many commercially available alcohol solutions contain ingredients which are injurious to container components, and therefore, should not be used. Cartridges should not be immersed in any solution.","Manufactured and Distributed by Novocol Pharmaceutical of Canada, Inc. Cambridge, Ontario, N1R 6X3, Canada Rev. 03/2020 (2780-3)"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION As with all local anesthetics, the dose varies and depends upon the area to be anesthetized, the vascularity of the tissues, individual tolerance and the technique of anesthesia. The lowest dose needed to provide effective anesthesia should be administered. For specific techniques and procedures refer to standard dental manuals and textbooks. For infiltration and block injections in the upper or lower jaw, the average dose of 1 cartridge will usually suffice. Each cartridge contains 1.7 mL (34 mg of 2% or 51 mg of 3%). 5.3 cartridges (180 mg of the 2% solution or 270 mg of the 3% solution) are usually adequate to effect anesthesia of the entire oral cavity. Whenever a larger dose seems to be necessary for an extensive procedure, the maximum dose should be calculated according to the patient's weight. A dose of up to 3 mg per pound of body weight may be administered. At any single dental sitting the total dose for all injected sites should not exceed 400 mg in adults. The maximum pediatric dose should be carefully calculated. Maximum dose for pediatric population = Child's Weight (lbs.) 150 × Maximum Recommended Dose for Adults (400 mg) The following table, approximating these calculations, may also be used as a guide. This table is based upon a recommended maximum for larger pediatric population of 5.3 cartridges (the maximum recommended adult dose) during any single dental sitting, regardless of the pediatric patient's weight or (for 2% mepivacaine) calulated maximum amount of drug: Maximum Allowable Dosage* 3% Mepivacaine 2% Mepivacaine 1:20,000 Levonordefrin 3 mg/lb 3mg/lb (270 mg max.) (180 mg max.) Weight (lb.) mg Number of Cartridges mg Number of Cartridges 20 60 1.2 60 1.8 30 90 1.8 90 2.6 40 120 2.3 120 3.5 50 150 2.9 150 4.4 60 180 3.5 180 5.3 80 240 4.7 180 5.3 100 270 5.3 180 5.3 120 270 5.3 180 5.3 *Adapted from Malamed, Stanley F. Handbook of medical emergencies in the dental office, ed. 2, St. Louis, 1982. The C.V. Mosby Co. When using Mepivacine HCl Injection USP for infiltration or regional block anesthesia, injection should always be made slowly and with frequent aspiration. Any unused portion of a cartridge should be discarded. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."],"spl_product_data_elements":["Mepivacaine Mepivacaine Hydrochloride Mepivacaine Hydrochloride Mepivacaine Sodium Chloride Water"],"spl_unclassified_section_table":["
CARTRIDGE
Each mL contains:2%3%
Mepivacaine Hydrochloride20 mg30 mg
Levonordefrin0.05 mg-
Sodium Chloride4 mg6 mg
Potassium metabisulfite1.2 mg-
Edetate disodium0.25 mg-
Sodium Hydroxide q.s. ad pH; Hydrochloric Acid0.5 mg-
Water For Injection, qs. ad.1 mL1 mL
The pH of the 2% cartridge solution is adjusted between 3.3 and 5.5 with NaOH.
The pH of the 3% cartridge solution is adjusted between 4.5 and 6.8 with NaOH.
"],"dosage_and_administration_table":["
Child's Weight (lbs.) 150×Maximum Recommended Dose for Adults (400 mg)
","
3% Mepivacaine2% Mepivacaine
1:20,000 Levonordefrin
3 mg/lb3mg/lb
(270 mg max.)(180 mg max.)
Weight (lb.)mgNumber of CartridgesmgNumber of Cartridges
20601.2601.8
30901.8902.6
401202.31203.5
501502.91504.4
601803.51805.3
802404.71805.3
1002705.31805.3
1202705.31805.3
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1.7 mL Cartridge Carton NDC 43128-005-35 Mepivacaine Mepivacaine HCl 3% (30 mg/mL) Injection without Vasoconstrictor (Mepivacaine HCl Injection, USP) REF: 08-A0003 Contains: 50 single-dose cartridges/1.7 mL each For Dental Block and Infiltration Only Rx Only Made in Canada for: NDC, Inc., 402 BNA Drive, Suite 500 Nashville, TN 37217 | www.quala.com PRINCIPAL DISPLAY PANEL - 1.7 mL Cartridge Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of Mepivacaine HCl in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted."]},"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"tricyclic antidepressants or monoamine oxidase inhibitors","severity":"major","mechanism":"interaction with vasopressors in local anesthetic solutions","management":"concurrent use should generally be avoided; if necessary, careful patient monitoring is essential","clinicalEffect":"severe, prolonged hypertension"},{"drug":"ergot-type oxytocic drugs","severity":"major","mechanism":"interaction with vasopressor drugs","management":"use with caution; avoid concurrent administration if possible","clinicalEffect":"severe, persistent hypertension or cerebrovascular accidents"},{"drug":"Phenothiazines and butyrophenones","severity":"major","mechanism":"reduction or reversal of the pressor effect of Epinephrine","management":"use with caution; monitor for reduced pressor response","clinicalEffect":"reduced effectiveness of Epinephrine"},{"drug":"potent inhalation anesthetics","severity":"major","mechanism":"interaction with vasoconstrictors in local anesthetics","management":"use with caution; monitor for arrhythmias","clinicalEffect":"serious cardiac arrhythmias"},{"drug":"drugs associated with methemoglobinemia","severity":"major","mechanism":"concurrent exposure to local anesthetics and methemoglobinemia-inducing drugs","management":"use with caution; monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"}],"commonSideEffects":[{"effect":"Nervousness","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"","severity":"common","organSystem":""},{"effect":"Tremors","drugRate":"","severity":"common","organSystem":""},{"effect":"Drowsiness","drugRate":"","severity":"common","organSystem":""},{"effect":"Sweating","drugRate":"","severity":"common","organSystem":""},{"effect":"Feeling of faintness","drugRate":"","severity":"common","organSystem":""},{"effect":"Cutaneous lesions","drugRate":"","severity":"common","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Localized puffiness and swelling","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Mepivacaine is contraindicated in patients with a known hypersensitivity to amide-type local anesthetics."],"seriousAdverseEvents":[{"effect":"Persistent paresthesias of lips, tongue, and oral tissues","drugRate":"","severity":"serious"},{"effect":"Convulsions","drugRate":"","severity":"serious"},{"effect":"Unconsciousness","drugRate":"","severity":"serious"},{"effect":"Respiratory arrest","drugRate":"","severity":"serious"},{"effect":"Cerebral hypoxia","drugRate":"","severity":"serious"},{"effect":"Seizure","drugRate":"","severity":"serious"},{"effect":"Cardiovascular catastrophe","drugRate":"","severity":"serious"},{"effect":"Anaphylactoid reactions","drugRate":"","severity":"serious"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MEPIVACAINE HYDROCHLORIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:50:14.379289+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:51:05.229730+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:50:20.783005+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEPIVACAINE HYDROCHLORIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:50:21.072330+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:50:13.263914+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:51:01.073938+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:50:13.263940+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium channel alpha subunit blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:50:22.823208+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:50:53.457979+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200440/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:50:22.428087+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Reactions to Mepivacaine are characteristic of those associated with other amide-type local anesthetics. Systemic adverse reactions involving the central nervous system and the cardiovascular system usually result from high plasma levels (which may be due to excessive dosage, rapid absorption, inadvertent intravascular injection, or slow metabolic degradation), injection technique, or volume of injection. A small number of reactions may result from hypersensitivity, idiosyncras","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:50:26.674659+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:50:29.840552+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA088387","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:50:13.263945+00:00"}},"_dailymed":{"setId":"af6ff5f6-7221-421b-9b7c-8fcee4a47772","title":"SCANDONEST 3% PLAIN (MEPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [SEPTODONT, INC.]"},"aiSummary":"Mepivacaine Hydrochloride is a marketed local anesthetic primarily used for dental procedures. Its key strength lies in its established use and safety profile, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent approaches expiration.","_scrapedAt":"2026-03-28T00:33:49.002Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T05:51:05.229818+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"mepivacaine-hydrochloride-local-anesthesia-for-dental-pr","name":"Local anesthesia for dental procedures","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT04454203","phase":"PHASE4","title":"Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension","status":"RECRUITING","sponsor":"Duke University","startDate":"2021-02-05","conditions":"Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty","enrollment":40},{"nctId":"NCT07414797","phase":"NA","title":"Discomfort Following Oral Biopsy Comparing Laser and Punch Biopsy","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2023-01-11","conditions":"Oral Lichen Planus, Biopsy","enrollment":112},{"nctId":"NCT05445921","phase":"PHASE1, PHASE2","title":"Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2022-09-01","conditions":"Anosmia, Hyposmia, Parosmia","enrollment":20},{"nctId":"NCT07239999","phase":"PHASE4","title":"Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2026-03-31","conditions":"Recovery Period, Anesthesia","enrollment":170},{"nctId":"NCT07298746","phase":"NA","title":"Oct Angiography Changes After Local Anesthesia in Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-12","conditions":"OCTA Changes With Local Anesthesia","enrollment":100},{"nctId":"NCT07239817","phase":"NA","title":"PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach","status":"RECRUITING","sponsor":"ASST Gaetano Pini-CTO","startDate":"2025-12-01","conditions":"Hip Fractures, Arthroplasty, Replacement, Hip, Pain, Postoperative","enrollment":100},{"nctId":"NCT07239505","phase":"NA","title":"A Randomized Controlled Trial Evaluating Whether Pre-operative Trinase Reduces Post-operative Pain in Patients With Symptomatic Irreversible Pulpitis Compared to Placebo, Using VAS Scores and Analgesic Intake Over 48 Hours.","status":"RECRUITING","sponsor":"Fayoum University","startDate":"2025-08-01","conditions":"Symptomatic Irreversible Pulpitis (SIP), Postoperative Pain After Endodontic Treatment, Endodontic Disease","enrollment":182},{"nctId":"NCT07246434","phase":"NA","title":"Platelet-Rich Plasma Versus Home-Based Exercise for Partial-Thickness Supraspinatus Tears","status":"COMPLETED","sponsor":"Universidad de Extremadura","startDate":"2023-09-01","conditions":"Rotator Cuff Injuries, Shoulder Joint, Shoulder Pain","enrollment":40},{"nctId":"NCT06927726","phase":"NA","title":"Assessment of Anesthetic Efficacy and Hemodynamic Stability of Two LA Drugs for Hypertensive Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Tanta University","startDate":"2025-01-10","conditions":"Hypertension","enrollment":60},{"nctId":"NCT06253806","phase":"PHASE2","title":"Stellate Ganglion Block for COVID-induced Parosmia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2023-10-25","conditions":"COVID-19-Induced Parosmia","enrollment":48},{"nctId":"NCT06005480","phase":"PHASE1","title":"Understanding Rebound Pain After Regional Anesthesia Resolution in Healthy Volunteers","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-09-28","conditions":"Regional Anesthesia Morbidity, Pain, Acute, Healthy","enrollment":40},{"nctId":"NCT05444751","phase":"PHASE3","title":"GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-03-22","conditions":"Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Radiculopathy","enrollment":142},{"nctId":"NCT05980546","phase":"PHASE4","title":"Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2023-06-07","conditions":"Total Knee Replacement, Genicular Nerve Block, Opioid Use","enrollment":244},{"nctId":"NCT07183904","phase":"NA","title":"Nerve and Hematoma Blocks for Pain Relief During Distal Radius Fracture Reduction","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2024-01-01","conditions":"Acute Distal Radius Fracture, Displaced Distal Radius Fracture","enrollment":180},{"nctId":"NCT07178379","phase":"NA","title":"Hysteroscopy Anesthesia for Relief of Pain","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-09-06","conditions":"Pain Management, Outpatient Hysteroscopy, Local Anesthesia","enrollment":70},{"nctId":"NCT07156396","phase":"NA","title":"SleeperOne vs. Conventional Infiltration: Pain Perception in Mandibular Primary Molar Extraction","status":"NOT_YET_RECRUITING","sponsor":"Ameera Alaa Eldin Abdalazim Khalifa","startDate":"2025-09-02","conditions":"Dental Anxiety, Pain, Pain Management","enrollment":28},{"nctId":"NCT06291727","phase":"PHASE4","title":"Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2024-02-16","conditions":"Anesthesia, Spinal, Arthroplasty, Replacement, Knee","enrollment":138},{"nctId":"NCT07124052","phase":"NA","title":"Comparison of Pain Perception in A Group of Pediatric Patients Undergoing Maxillary Primary Molar Extraction Using A Novel Anesthetic Device Versus Traditional Infiltration","status":"NOT_YET_RECRUITING","sponsor":"Aya Hesham ElSayed Mohamed ElTanahy","startDate":"2025-08-18","conditions":"Pain, Extraction, Tooth","enrollment":2},{"nctId":"NCT05425979","phase":"PHASE4","title":"Mepivacaine Versus Bupivacaine Onset Time in Ultrasound-guided Ankle Blocks","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2024-03-11","conditions":"Ankle Block, Foot Surgery","enrollment":50},{"nctId":"NCT07079449","phase":"NA","title":"Comparison of Lidocaine, Mepivacaine, and Dry Needling in Myofascial Pain Syndrome","status":"COMPLETED","sponsor":"Sümer Münevveroğlu","startDate":"2025-05-01","conditions":"Myofascial Pain Syndrome, Temporomandibular Joint Disorders, Facial Pain","enrollment":75},{"nctId":"NCT07013071","phase":"PHASE4","title":"Hemodynamic Effects of Different Vasoconstrictors in Mandibular Exodontia","status":"COMPLETED","sponsor":"King Abdulaziz University","startDate":"2024-02-10","conditions":"Hemodynamics, Pain, ASA I-II Requiring Simple Dental Extraction of a Mandibular Tooth","enrollment":52},{"nctId":"NCT05688943","phase":"NA","title":"Comparative Analysis of Spinal Anesthesia Versus General Anesthesia for vNOTES","status":"ENROLLING_BY_INVITATION","sponsor":"University of Kansas Medical Center","startDate":"2023-03-01","conditions":"Anesthesia, Tubal Ligation","enrollment":20},{"nctId":"NCT06725823","phase":"NA","title":"Therapeutic Effect of Shoulder Anterior Capsular Block Versus Suprascapular Nerve Block in Patients With Frozen Shoulder","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-01-10","conditions":"Frozen Shoulder","enrollment":50},{"nctId":"NCT06047366","phase":"PHASE4","title":"Combination of Buffered Anesthetic to Treat Mandibular Molars","status":"TERMINATED","sponsor":"Indiana University","startDate":"2023-12-05","conditions":"Symptomatic Irreversible Pulpitis","enrollment":40},{"nctId":"NCT06155903","phase":"NA","title":"Peripheral Nerve Blocks vs Selective Spinal Anesthesia in Patients With Femur Fracture","status":"COMPLETED","sponsor":"Federico II University","startDate":"2023-12-31","conditions":"Femur Fracture, Peripheral Nerve Block, Spinal Anesthesia","enrollment":78},{"nctId":"NCT06939491","phase":"NA","title":"Comparison of Ultrasound-guided Electrolysis Therapy vs. Sham Electrolysis in Patients With Patellar Tendinopathy: A Prospective Randomized Study Including MRI and Shear-wave Ultrasound Elastography Imaging","status":"ENROLLING_BY_INVITATION","sponsor":"Gymna Uniphy","startDate":"2024-10-29","conditions":"Patellar Tendinopathy / Jumpers Knee","enrollment":74},{"nctId":"NCT05728151","phase":"NA","title":"Comparing General Anesthesia With Single Injection Peribulbar Block With 3 Different Drugs","status":"COMPLETED","sponsor":"Research Institute of Ophthalmology, Egypt","startDate":"2022-02-22","conditions":"Pediatric Squint Surgeries","enrollment":55},{"nctId":"NCT06166394","phase":"","title":"Spinal Hypobaric Local Anesthetic Study","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2023-06-09","conditions":"Anesthesia, Local","enrollment":60},{"nctId":"NCT06808724","phase":"","title":"Clinical Influence of Different Surface Treatments on Implant Stabiity","status":"RECRUITING","sponsor":"International Piezosurgery Academy","startDate":"2025-01-31","conditions":"Edentulous Alveolar Ridge","enrollment":32},{"nctId":"NCT05875519","phase":"NA","title":"Healing Process and Blood Sugar Level Following Local Anesthetic Infiltration With and Without Vasoconstrictor","status":"COMPLETED","sponsor":"Minia University","startDate":"2023-05-20","conditions":"Diabetes, Anesthesia, Local","enrollment":40},{"nctId":"NCT04084288","phase":"NA","title":"Acupuncture for Low-Dose Opioid for TKA Replacement","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-08-21","conditions":"Knee Osteoarthritis, Pain, Postoperative, Acupuncture","enrollment":41},{"nctId":"NCT03094663","phase":"PHASE4","title":"Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-02-28","conditions":"Knee Arthropathy","enrollment":86},{"nctId":"NCT05839548","phase":"PHASE3","title":"Articaine Efficacy and Safety for 3 Years Old Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qassim Health Cluster","startDate":"2023-07-01","conditions":"Dental Caries in Children, Dental Diseases, Pulp Disease, Dental","enrollment":200},{"nctId":"NCT03090152","phase":"PHASE4","title":"Minimal Opioid Use After Total Hip Replacement (THR)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-03-08","conditions":"Osteoarthritis, Hip","enrollment":180},{"nctId":"NCT03711734","phase":"NA","title":"Acupuncture ACL (Anterior Cruciate Ligament)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2018-11-01","conditions":"ACL, ACL Injury, Anterior Cruciate Ligament Injury","enrollment":40},{"nctId":"NCT06679894","phase":"","title":"Evaluation of Implant Stability Changes in Sites Prepared with Different Osseodensification Techniques: a Prospective Observational Clinical Study","status":"COMPLETED","sponsor":"International Piezosurgery Academy","startDate":"2024-02-15","conditions":"Edentulous, Alveolar Process Atrophy","enrollment":12},{"nctId":"NCT05765682","phase":"NA","title":"Mepivacaine Vs. Bupivacaine Spinal for TKA","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2023-03-13","conditions":"Total Knee Replacement","enrollment":160},{"nctId":"NCT06128590","phase":"NA","title":"Photobiomodulation for Controlling Pre-Local Anesthetic Injection Pain","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2023-02-15","conditions":"Fear Needles","enrollment":50},{"nctId":"NCT06271174","phase":"PHASE3","title":"Avoid With Locoregional Analgesia Persistant Postoperative Pain In Children","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-06-06","conditions":"Persistent Postoperative Pain","enrollment":208},{"nctId":"NCT06130514","phase":"NA","title":"The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Sympathetic Ganglion Block","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University","startDate":"2024-07-10","conditions":"Chronic Pain, Neuropathic Pain, Complex Regional Pain Syndromes","enrollment":118},{"nctId":"NCT02058303","phase":"PHASE4","title":"Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery","status":"TERMINATED","sponsor":"Jose Soberon, MD","startDate":"2014-02","conditions":"Hand Injuries, Wrist Injuries, Finger Injuries","enrollment":37},{"nctId":"NCT06092541","phase":"NA","title":"Pericervical Analgesia Versus Analesia With Nitrous Oxide (N2O) in Outpatien Operative Hysteroscopy With Miniresector","status":"COMPLETED","sponsor":"Ospedale degli Infermi di Biella","startDate":"2023-10-02","conditions":"Hysteroscopy","enrollment":50},{"nctId":"NCT01860417","phase":"PHASE1, PHASE2","title":"Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)","status":"COMPLETED","sponsor":"Red de Terapia Celular","startDate":"2013-06-21","conditions":"Degenerative Disc Disease, Intervertebral Disc Disease, Low Back Pain","enrollment":24},{"nctId":"NCT06333743","phase":"NA","title":"Laser Ablation in the Treatment of High-grade Cervical Lesions","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05","conditions":"High-Grade Squamous Intraepithelial Lesions","enrollment":308},{"nctId":"NCT06268912","phase":"NA","title":"Cryoanalgesia for Irreversible Pulpitis","status":"COMPLETED","sponsor":"Universitat Internacional de Catalunya","startDate":"2022-09-07","conditions":"Pulpitis - Irreversible","enrollment":20},{"nctId":"NCT06256042","phase":"NA","title":"Effectiveness of Arthrocentesis and the Occlusal Splint in Treatment of the TMJ","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-05-30","conditions":"Temporomandibular Joint Disc Displacement, Anterior Disc Displacement","enrollment":24},{"nctId":"NCT06246591","phase":"NA","title":"Extracorporeal Shockwave Therapy vs Mesotherapy in the Treatment of Myofascial Pain Syndrome: a Case-control Study","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2022-02-01","conditions":"Myofascial Pain Syndrome, Trigger Point Pain, Myofascial","enrollment":54},{"nctId":"NCT05222828","phase":"PHASE2","title":"Effects of Mepivacaine on the Neurological Sequelae of Cerebral Infarction","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-22","conditions":"Ischemic Stroke","enrollment":38},{"nctId":"NCT06172400","phase":"NA","title":"Wide Awake Open Carpal Tunnel Release With or Without a Tourniquet","status":"UNKNOWN","sponsor":"Region Skane","startDate":"2024-01-09","conditions":"Carpal Tunnel Syndrome","enrollment":120},{"nctId":"NCT06173492","phase":"NA","title":"Platelet Rich Fibrin (PRF) in Socket Preservation Technique","status":"UNKNOWN","sponsor":"University of Naples","startDate":"2023-01-11","conditions":"Alveolar Bone Loss, Tooth Extraction","enrollment":80},{"nctId":"NCT05619796","phase":"NA","title":"Assessment of Clinical & Radiographic Efficiency of Manual & Pediatric Rotary Systems in Primary Root Canal Preparation","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-09-04","conditions":"Manual; Rotation, Obturation, Post Operative Pain","enrollment":60},{"nctId":"NCT05478902","phase":"NA","title":"Effectiveness of Non-surgical Management in Rotator Cuff Calcific Tendinopathy (THE EFFECT TRIAL)","status":"UNKNOWN","sponsor":"University of Valencia","startDate":"2023-05-01","conditions":"Rotator Cuff Tendinosis, Rotator Cuff Injuries, Shoulder Tendinitis","enrollment":116},{"nctId":"NCT03922412","phase":"NA","title":"Plantar Compartment Block Versus Sciatic Block in Hallux Valgus Ambulatory Surgery","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2019-06-24","conditions":"Anesthesia","enrollment":60},{"nctId":"NCT04876989","phase":"NA","title":"The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Paravertebral Block","status":"COMPLETED","sponsor":"Seoul National University","startDate":"2021-07-21","conditions":"Complex Regional Pain Syndromes, Postherpetic Neuralgia, Phantom Limb Pain","enrollment":69},{"nctId":"NCT05201313","phase":"PHASE3","title":"Efficacy and Safety of the Application of Local Anaesthetic in Spray to Repair of 1st- 2nd Perineal Lacerations","status":"COMPLETED","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2022-01-20","conditions":"Vaginal Discharge, Perineum; Rupture, Analgesia","enrollment":136},{"nctId":"NCT05908305","phase":"PHASE4","title":"Impact of Tramadol Addiction On Dental Anesthesia Success","status":"UNKNOWN","sponsor":"University of Algiers","startDate":"2023-06-10","conditions":"Dental Pain and Sensation Disorder, Anesthesia, Local, Addiction, Opioid","enrollment":300},{"nctId":"NCT05782634","phase":"NA","title":"Insertion of Immediate Cortical Satellite Implants With Immediate Loading","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-06-01","conditions":"Immediate Loading , Satellite Implant , Immediate Implant","enrollment":6},{"nctId":"NCT04477317","phase":"PHASE3","title":"Anesthetic Efficacy of %4Alexadricaine Versus %2 Mepicaine-L in Children","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-08-01","conditions":"Local Anesthesia","enrollment":10},{"nctId":"NCT05700500","phase":"NA","title":"Comparison of Focused Shock Waves or Ultrasound-Guided Needling and Lavage in Patients With Calcifying Tendinopathy of the Shoulder","status":"UNKNOWN","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2021-01-01","conditions":"Calcific Tendinopathy of Shoulders, Extracorporeal Shockwave Therapy, Ultrasound Guided Barbotage Therapy","enrollment":165},{"nctId":"NCT02795598","phase":"NA","title":"Diaphragmatic Dysfunction After Ultrasound-guided Supraclavicular Block With Single or Double Injection Technique","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2016-08","conditions":"Anesthesia","enrollment":""},{"nctId":"NCT05533723","phase":"","title":"Comparison Between Endoscopic Epidural Neuroplasty and Percutaneous Epidural Neuroplasty in Low Back and Radicular Pain","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2018-10-10","conditions":"Low Back Pain, Radiculopathy","enrollment":107},{"nctId":"NCT03432650","phase":"PHASE3","title":"Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2018-06-01","conditions":"Hip Disease","enrollment":96},{"nctId":"NCT04257682","phase":"PHASE4","title":"Regional Anesthesia in Total Hip and Knee Arthroplasty","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-09","conditions":"Knee Osteoarthritis, Hip Osteoarthritis","enrollment":135},{"nctId":"NCT03211949","phase":"NA","title":"Ultrasound Guided Topographic Mapping of Medial Antebrachial Cutaneous Nerve","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2014-09","conditions":"Nerve Block, Surgery, Anesthesia","enrollment":150},{"nctId":"NCT05484648","phase":"PHASE4","title":"Dexamethasone or Dexmedetomidine as Adjunct in Fascia Iliaca Block During Positioning for Sub-arachnoid Block & Post-operative Analgesia After Femur Neck Fracture Surgery: A Randomized Control Trial","status":"UNKNOWN","sponsor":"Aga Khan University Hospital, Pakistan","startDate":"2023-01-01","conditions":"Post Operative Pain","enrollment":60},{"nctId":"NCT05338983","phase":"NA","title":"Effect of Different Approaches of Delivering Local Dental Anesthesia on Pain Perception in Children.","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-05-01","conditions":"Pain, Local Anesthetics, Epinephrine","enrollment":80},{"nctId":"NCT03365752","phase":"PHASE2","title":"Chloroprocaine Spinal for Outpatient Knee Surgery","status":"TERMINATED","sponsor":"Hospital for Special Surgery, New York","startDate":"2018-06-24","conditions":"Knee Arthroscopy","enrollment":39},{"nctId":"NCT04897308","phase":"NA","title":"Best Treatment Modality of Frozen Shoulder","status":"COMPLETED","sponsor":"Sohag University","startDate":"2021-05-01","conditions":"Shoulder Adhesive Capsulitis","enrollment":54},{"nctId":"NCT05252117","phase":"PHASE4","title":"Uterovaginal Plexus Block With Articaine for Intrauterine Device Placement Patients Who Are Indicated for the Use of Copper IUD as a Contraceptive Method Will be Invited to Participate in This Research.","status":"UNKNOWN","sponsor":"Universidade do Vale do Sapucai","startDate":"2021-02-01","conditions":"Contraception, IUD, Anesthesia, Local","enrollment":240},{"nctId":"NCT05238727","phase":"NA","title":"Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-03","conditions":"Symptomatic Irreversible Pulpitis","enrollment":75},{"nctId":"NCT05239078","phase":"NA","title":"Comparative Evaluation of Pulpal Anaesthetic Efficacy of Different Anaesthetic Solutions for Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis","status":"COMPLETED","sponsor":"Dr. Vivek Aggarwal","startDate":"2016-03-01","conditions":"Pulpitis","enrollment":120},{"nctId":"NCT01913574","phase":"NA","title":"Efficacy Study of Acupuncture to Treat the Upper Abdominal Pain of Cancer Patients","status":"COMPLETED","sponsor":"Daegu Catholic University Medical Center","startDate":"2013-03","conditions":"Abdominal Pain","enrollment":14},{"nctId":"NCT01913587","phase":"NA","title":"Efficacy Study of Acupuncture on Spinal Compression Fracture","status":"COMPLETED","sponsor":"Daegu Catholic University Medical Center","startDate":"2013-03","conditions":"Spinal Compression Fracture","enrollment":14},{"nctId":"NCT05162885","phase":"EARLY_PHASE1","title":"Effect of Sodium Alendronate on the Final Implant Stability.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-05-01","conditions":"Anterior Labial Wall Defect","enrollment":24},{"nctId":"NCT05136625","phase":"NA","title":"Sphenopalatine Ganglion Block and Pain Management in Neurosurgery","status":"UNKNOWN","sponsor":"University Hospital of Ferrara","startDate":"2021-02-01","conditions":"Post Operative Pain, Craniofacial Pain","enrollment":84},{"nctId":"NCT05136534","phase":"NA","title":"Spinal Versus Local Anesthesia for Hernia Repair","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2019-01-10","conditions":"Hernia, Inguinal","enrollment":132},{"nctId":"NCT03567590","phase":"NA","title":"The Efficacy and Safety of Sphenopalatine Ganglion Pulsed Radiofrequency Treatment for Cluster Headache","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2018-07-05","conditions":"Cluster Headache","enrollment":80},{"nctId":"NCT04479176","phase":"","title":"Comparison of Two Methods of Transnasal Sphenopalatine Ganglion Block","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2021-03-10","conditions":"Sphenopalatine Ganglion Block","enrollment":74},{"nctId":"NCT03396991","phase":"","title":"Comparative Evaluation of Two Different Post-Operative Analgesia After Hallux Valgus Correction","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2017-07-01","conditions":"Pain, Postoperative","enrollment":26},{"nctId":"NCT03838874","phase":"PHASE2, PHASE3","title":"Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-02-25","conditions":"Knee Osteoarthritis, Hip Osteoarthritis","enrollment":154},{"nctId":"NCT04822415","phase":"NA","title":"Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2014-12","conditions":"Symptomatic Irreversible Pulpitis","enrollment":330},{"nctId":"NCT04947267","phase":"PHASE2","title":"To Compare the Pulpal Oxygen Saturation Level After Administering Mepivacaine With and Without Vasoconstrictor","status":"COMPLETED","sponsor":"Afshan Amjad Ali","startDate":"2018-05-30","conditions":"LOCAL ANESTHESIA","enrollment":60},{"nctId":"NCT04113954","phase":"PHASE1","title":"Detecting Compartment Syndrome Pain in the Presence of Regional Anesthesia in Healthy Volunteers","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-29","conditions":"Compartment Syndrome of Leg, Healthy","enrollment":42},{"nctId":"NCT03948386","phase":"PHASE4","title":"3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2019-05-13","conditions":"Osteoarthritis, Hip","enrollment":159},{"nctId":"NCT03390426","phase":"PHASE4","title":"Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-05-03","conditions":"Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty","enrollment":31},{"nctId":"NCT03063255","phase":"PHASE4","title":"Comparison of Obturator Nerve Blockade and Neuromuscular Blockade","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-04-25","conditions":"Cancer of Bladder","enrollment":60},{"nctId":"NCT04637854","phase":"NA","title":"Postural Analysis During Dental Surgery","status":"COMPLETED","sponsor":"University of Milan","startDate":"2017-03-01","conditions":"Postural Low Back Pain","enrollment":65},{"nctId":"NCT01574807","phase":"PHASE4","title":"The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2012-05","conditions":"Pain","enrollment":100},{"nctId":"NCT04037449","phase":"NA","title":"Transversus Abdominis Plane Block in the Analgesia of Acute Pancreatitis","status":"UNKNOWN","sponsor":"Consorci Sanitari Integral","startDate":"2020-11-30","conditions":"Pancreatitis, Acute","enrollment":44},{"nctId":"NCT04561921","phase":"NA","title":"Effect of Magnesium Sulphate Added to Mepivacaine Hydrochloride on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis in Mandibular Molars: A Randomized Clinical Trial.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-10-22","conditions":"Success of Inferior Alveolar Nerve Block","enrollment":56},{"nctId":"NCT04509440","phase":"NA","title":"Efficacy of Neural Prolotherapy for Treatment of Anserine Bursitis \"NPCAB\"","status":"COMPLETED","sponsor":"University of Alexandria","startDate":"2018-05-01","conditions":"Anserine Bursitis","enrollment":43},{"nctId":"NCT04506450","phase":"NA","title":"Peripheral Nerve Block vs Spinal Anesthesia in Hip Surgery","status":"COMPLETED","sponsor":"Università Politecnica delle Marche","startDate":"2019-01-01","conditions":"Hip Arthroplasty","enrollment":100},{"nctId":"NCT04465149","phase":"NA","title":"Efficacy of Differents Anaesthetics in Mandibular Third Molar Germectomy","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-06-30","conditions":"Local Anesthetic Efficacy","enrollment":50},{"nctId":"NCT03138577","phase":"PHASE4","title":"Dose-Response Relationships for Hemidiaphragmatic Paresis Following Ultrasound-Guided Supraclavicular Block","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-02-12","conditions":"Surgery of Right Upper Extremity","enrollment":24},{"nctId":"NCT02325687","phase":"NA","title":"A Pilot Study of Biomarkers in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2015-01","conditions":"Obstructive Sleep Apnea","enrollment":50},{"nctId":"NCT03790540","phase":"PHASE2","title":"Pain Assessment During Mandibular Nerve Block Injection With the Aid of Dental Vibe Tool in Pediatric Dental Patients","status":"COMPLETED","sponsor":"Nourhan M.Aly","startDate":"2018-12-01","conditions":"Anesthesia, Local","enrollment":60},{"nctId":"NCT02406703","phase":"","title":"The Impact of Chloroprocaine 3% for Ambulatory Foot Surgery on Perioperative Process Costs","status":"COMPLETED","sponsor":"Ospedale Regionale Bellinzona e Valli","startDate":"2014-01","conditions":"Impact of Anesthetic Choice on Costs","enrollment":100},{"nctId":"NCT02584452","phase":"NA","title":"Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-11-03","conditions":"Rupture of Anterior Cruciate Ligament, Tear of Anterior Cruciate Ligament","enrollment":59},{"nctId":"NCT01522534","phase":"PHASE3","title":"Randomized Double Blind Controlled Trial Comparing a Blind Sciatic Nerve Block in the Popliteal Fossa to Intravenous Morphine for Traumatic Severe Acute Pain in the Prehospital Setting","status":"TERMINATED","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2012-01","conditions":"Injuries, Pain, Emergencies","enrollment":26},{"nctId":"NCT02996591","phase":"PHASE4","title":"Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-01","conditions":"Nerve Block, General Anesthesia, Spinal Anesthesia","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":24,"reaction":"DYSPNOEA"},{"count":22,"reaction":"HYPOTENSION"},{"count":22,"reaction":"NAUSEA"},{"count":19,"reaction":"DIZZINESS"},{"count":18,"reaction":"PRURITUS"},{"count":16,"reaction":"DRUG INEFFECTIVE"},{"count":16,"reaction":"MONOPLEGIA"},{"count":14,"reaction":"BRADYCARDIA"},{"count":13,"reaction":"ARTHRALGIA"},{"count":13,"reaction":"SYNCOPE"}],"administration":{"route":"Submucosal"},"crossReferences":{"chemblId":"CHEMBL1200440"},"_approvalHistory":[{"date":"20170608","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19890912","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19841010","type":"ORIG","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"20000406","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19870617","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19870408","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19960304","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19920512","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19920207","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"20181102","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"20041012","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"20030123","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19880505","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19940804","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"20070618","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19860114","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19930916","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19850910","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"20000406","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"},{"date":"19890912","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088387"}],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"MEPIVACAINE HYDROCHLORIDE","genericName":"MEPIVACAINE HYDROCHLORIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1960","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T05:51:05.229818+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}